Compare Gilead Sciences, Inc. (GILD) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Riot Platforms Inc — how do they compare? Gilead Sciences, Inc. trades at $134 (market cap $163.51B), while Riot Platforms Inc trades at $18.51 (market cap $7.60B). The key difference: Gilead Sciences, Inc. is far larger — about 21.5× Riot Platforms Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| GILD | RIOT | |
|---|---|---|
Market Cap | $163.51B | $7.60B |
Sector | Health | Technology |
52-Week High | $155.80 | $28.67 |
52-Week Low | $108.22 | $11.03 |
Enterprise Value | $178.05B | $8.27B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
RIOT trades at $18.89, down 6.44% over 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of $663.18M in 2025 despite $647.44M revenue, reflecting negative profit margins. Recent earnings missed expectations in Q4 2025 and Q1 2026. Analyst consensus remains strongly bullish with a $27.86 price target, supported by 17 buy ratings. News highlights volatility amid Bitcoin price swings and Texas grid reliability concerns affecting data center operations.
Outlook is mixed: strong analyst support suggests upside potential, but persistent losses and operational cash flow deficits pose significant risks. Investors face exposure to cryptocurrency market volatility and execution challenges in expanding high-performance compute capacity. The stock's current price near support levels may attract buyers if fundamentals improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
